EP3640251
6,7,8,9-Tetrahýdró-3H-pýrasóló[4,3-f]ísókínólín-afleiður sem eru nytsamlegar við meðhöndlun á krabbameini
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
13.10.2017EP published:
8.12.2021EP application number:
19189010.2
EP translation filed:
22.2.2022Grant published:
15.3.2022EPO information:
European Patent Register
Max expiry date:
12.10.2037Expiry date:
12.10.2026Next due date:
31.10.2026
Title in English:
6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCERLanguage of the patent:
English
Timeline
Today
13.10.2017EP application
8.12.2021EP Publication
22.2.2022Translation submitted
15.3.2022Registration published
12.10.2026Expires
Owner
Name:
Astrazeneca ABAddress:
151 85 Södertälje, SE
Inventor
Name:
SCOTT, James StewartAddress:
Cambridge Cambridgeshire CB4 0WG, GB
Name:
BARLAAM, Bernard ChristopheAddress:
Cambridge Cambridgeshire CB4 0WG, GB
Name:
YANG, BinAddress:
Waltham, MA 02451, US
Name:
MOSS, Thomas AndrewAddress:
Cambridge Cambridgeshire CB4 0WG, GB
Name:
HUGHES, Samantha JayneAddress:
Cambridge Cambridgeshire CB4 0WG, GB
Name:
NISSINK, Johannes Wilhelmus MariaAddress:
Cambridge Canbridgeshire CB4 0WG, GB
Name:
O'DONOVAN, Daniel HillebrandAddress:
Cambridge Cambridgeshire CB4 0WG, GB
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201662411799 PDate:
24.10.2016Country:
US
Number:
201662435159 PDate:
16.12.2016Country:
US
Classification
Categories:
C07D 471/04, A61K 31/4738, A61K 31/497, A61P 35/00
Annual fees
Number
Paid
Expires
Payer
Number: 6
Paid: 24.10.2022
Expires: 12.10.2023
Payer: Árnason Faktor ehf.
Number: 7
Paid: 13.10.2023
Expires: 12.10.2024
Payer: Árnason Faktor ehf.
Number: 8
Paid: 17.9.2024
Expires: 12.10.2025
Payer: Árnason Faktor ehf.
Number: 9
Paid: 14.10.2025
Expires: 12.10.2026
Payer: Árnason Faktor ehf.